SCHEMBL4487807

SCHEMBL4487807

COC(=O)c1ccccc1S(=O)(=O)c1cnc2nc(-c3ccc(F)cc3)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
CASP3 P42574 1/20 0.47
RAB9A P51151 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
SLC6A4 P31645 2/20 0.46
SLC6A3 Q01959 2/20 0.46
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CA9 Q16790 2/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA5A P35218 1/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4070865 0.84 SMN1; SMN2 (0.49) SMN1; SMN2NPC1CASP3RAB9ASENP8
SCHEMBL4071490 0.80 HTR2A (0.51) SMN1; SMN2MAPTCA9ALDH1A1HPGD
SCHEMBL4066087 0.79 MMP2 (0.50) SMN1; SMN2NPC1CASP3RAB9ASENP8
SCHEMBL4073448 0.72 SLC6A4 (0.43) SMN1; SMN2NPC1CASP3RAB9ASENP8
SCHEMBL4069732 0.72 HTR2A (0.43) MEN1KMT2ACA9ALDH1A1MMP1
SCHEMBL13713006 0.71 SLC6A4 (0.46) SMN1; SMN2NPC1CASP3RAB9ASENP8
SCHEMBL3157210 0.69 HTR2A (0.58) SLC6A4SLC6A3CA9CA1CA2
SCHEMBL3157221 0.69 HTR2A (0.58) SLC6A4SLC6A3CA9CA1CA2
SCHEMBL11661242 0.67 CA1 (0.73) NPC1MAPTMEN1KMT2ACA9
SCHEMBL4072144 0.66 MMP2 (0.47) CA9CA1CA2MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592456-B2 Arylsulfonylnaphthalene derivatives as 5HT2A antagonists MERCK SHARP & DOHME LIMITED (GB) 2009-09-22 US claimed
US-20070281952-A1 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists MERCK SHARPE & DOHME LIMITED (GB) 2007-12-06 US claimed
US-7592456-B2 Arylsulfonylnaphthalene derivatives as 5HT2A antagonists MERCK SHARP & DOHME LIMITED (GB) 2009-09-22 US disclosed
US-20070281952-A1 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists MERCK SHARPE & DOHME LIMITED (GB) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281952-A1 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists HTR2A, HTR2C, HTR1A SMN1; SMN2 200/4885NPC1 1772/4885CASP3 3062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.